We would like to thank David Franco as well as Lucile Warter, Danielle Morelle, and Ulrike Krause at GSK for supplying the RTS,S and AS01 used in this study as well as for their help in the study design. The authors are also to Fergal Hill and Alexandre Levert at
OSIVAX
for their support in respect to the IMX313 nanoparticle platform.
Osivax raises €8M for universal flu vaccine clinical trials